Evaluation of the Efficacy and Side Effects of Montelukast Sodium Combined with Salmeterol in Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome

Objective: To evaluate the efficacy and adverse reactions of Montelukast sodium combined with salmeterol in asthma-chronic obstructive pulmonary disease overlap syndrome.Methods: A total of 290 patients with asthma-chronic obstructive pulmonary disease overlap syndrome admitted to our hospital from June 2022 to July 2023 were divided into a study group and control group by random number table method, with 145 cases in each group.The control group was given salmeterol treatment, while the study group was given Montelukast sodium combined with salmeterol treatment for 6 consecutive months.The therapeutic effect, lung function before and after treatment, and treatment safety were evaluated and compared between the two groups.Results: After treatment, the total effective rate of the study group was higher than that of the control group, the pulmonary function indexes such as FVC and PEF were higher than those of the control group, and the incidence of treatment-related adverse reactions was lower than that of the control group, with statistical significance (P < 0.05).Conclusion: Montelukast sodium combined with salmeterol has higher efficacy and safety in the treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome, and can effectively improve the lung function of patients.